You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 120 No. 9, September 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Clinicopathologic Reports, Case Reports, and Small Case Series
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (8)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Discoloration of Intraocular Lens Subsequent to Rifabutin Use

Arch Ophthalmol. 2002;120:1211-1212.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A 63-year-old woman developed discoloration of the silicone intraocular lens (IOL) implants in both eyes after receiving 300 mg of rifabutin by mouth, once daily, for 101/2 months. Examination revealed a rose color to both implants, though the patient reported minimal visual deficit. We then investigated the effect of rifabutin on 3 different common IOL materials and found that it only affected silicone. Though rifabutin is well known to cause discoloration of body fluids and soft contact lenses, this case illustrates this process occurring in IOL implants.

Rifabutin is indicated for prophylaxis against Mycobacterium avium complex (MAC), which is primarily seen as a coinfection with human immunodeficiency virus (HIV). Shown to cause discoloration in certain body fluids, including tears, saliva, and perspiration, rifabutin prescribing guidelines specifically caution that soft contact lenses may be permanently stained subsequent to its use.1 However, to our knowledge, the occurrence in an IOL has not . . . [Full Text of this Article]

Report of a Case


Comment
Corresponding author and reprints: Alan Emory Irwin, MD, Division of Ophthalmology, Fletcher Allen Health Care, UHC Fourth Floor, Burlington, VT 05405 (e-mail: airwin@vtmednet.org).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.